Community/Retail

The Generic Pharmaceutical Association and its Biosimilars Council commend the Food and Drug Administration for hosting today's Arthritis Advisory Committee Meeting on the infliximab biosimilar, an important step toward advancing science and encouraging more choices for patients who previously would have to rely on costly brand biologic medicines.